From 2016 Matter
De Maintenance therapy with cabotegravir and rilpivirine Injectable Antiretrovirals works equally well when given monthly or every two months.
A combination of two injectable antiretrovirals, cabotegravir and rilpivirine, is equally effective in maintaining viral suppression when given once a month or every two months, the companies developing the long-acting regimen announced.
"The results from the ATLAS-2M study mean that people living with HIV can maintain viral suppression with six total treatments per year instead of one daily 365 oral treatment per year," said Kimberly Smith, MD, head of research. and global development of ViiV Healthcare.
Tests will evaluate the safety of bimonthly injection after certainty in monthly therapy!
😍😍😍The formulations ViiV integrase injectable antiretrovirals, Cabotegravir, in addition to Janssen non-nucleoside reverse transcriptase inhibitor, Rilpivirine (sold in tablet form as Edurant) have been studied in people who switched from standard oral antiretroviral therapy with undetectable viral load to those who started HIV treatment for the first time.
As reported at this year's Retrovirus and Opportunistic Infections Conference, the results of the Phase III ATLAS study showed that 92,5% of people randomly assigned to switch to the injectable regimen had undetectable HIV (less than 50 copies) 48 weeks later, as well as 95.5% of those who remained on their oral regimen. I see, here, a possible and hypothetical reduction in the damage to the labor relationship, if there is anything left of it !!! (…) Likewise, the FLAIR study showed similar rates of viral suppression in people new to treatment, 93,6% and 93,3%, respectively. In both studies, treatment with injectable cabotegravir and rilpivirine was generally safe and well tolerated, and serious adverse events were rare.
Most Common Reaction Was Injection Site Pain 😉The most common side effects were reactions at the injection site, such as pain and swelling, but these were typically mild to moderate and decreased over time. The results of the study presented at this summer's International AIDS Society Conference on HIV Science in Mexico City showed that people taking injectables reported a high level of satisfaction with treatment and preferred them to oral remedies. daily.
In these studies, cabotegravir and rilpivirine were administered by healthcare providers as two separate intramuscular injections, preferably in the buttocks. Participants were asked to return to the clinic every month within a seven-day window. Adherence was good in both studies, with almost all receiving monthly treatment within this window. However, returning to a clinic for injections every month can be inconvenient, and receiving treatment less often would be attractive. The ATLAS-2M phase III study was a direct comparison, in which participants were randomly assigned to receive injections of cabotegravir and rilpivirine every four weeks or every eight weeks.
They had no history of previous treatment failure. 😯🙄😔This international study included 1.045 people with HIV who were on their first or second antiretroviral regimen, had viral suppression for at least six months and had no history of previous treatment failure. ViiV and Janssen announced in press releases that the study had achieved its primary objective, showing that the effectiveness of the injectable cabotegravir / rilpivirine combo was similar in 48 weeks, regardless of whether it was administered once a month or every two months. In other words, cabotegravir / rilpivirine administered every eight weeks was found to be no less than every four weeks. The companies did not provide viral suppression rates or other detailed data at the time, indicating that they would be presented at an upcoming scientific conference. “We are excited to report that, for the first time since the HIV / AIDS epidemic began more than 30 years ago, our ATLAS-2M study demonstrated that it is possible to maintain suppression of HIV with an injectable regimen containing two drugs administered every two months, ”said Smith.